Pejman Cohan, MD
Endocrinology, Diabetes & Metabolism · Beverly Hills, CANPI 1225064884
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (39.7%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 59 manufacturers reported payments, led by Amgen at 43.1% of the total. Reporting peaked in 2019 at $19,662 and has fallen 91.0% since, to $1,760 in 2025. Among endocrinology, diabetes & metabolism clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 567 payments — averaging $59.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$15K
- Antares Pharma, Inc.$4K
- Recordati_rare_diseases_inc.$3K
- Chiasma, Inc.$2K
- Novo Nordisk$2K
- Lilly USA, LLC$1K
- plus $8K from 53 others
Across 116 payments — averaging $537.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ascendis Pharma Endocrinology Inc$34K
- Chiasma, Inc.$24K
- Amryt Pharma Holdings Ltd$4K
Across 2 payments — averaging $1,029,875 each. An ownership or investment interest held by the physician or an immediate family member.
- Corcept Therapeutics$2.1M
What the payments were for
- Consulting fees$4,80014%
- Speaking & faculty fees$13,47540%
- Travel & lodging$2,8188%
- Food & beverage$12,39837%
- Education$3991%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XYOSTED$4,001
- MYCAPSSA$1,800
- ISTURISA$216
- AFREZZA$107
- SIGNIFOR LAR$102
How this compares
$33,949 in reported general payments places this provider in the 90th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 258 | $326,334 |
| OzempicSemaglutide | 99 | $146,240 |
| GenotropinSomatropin | 34 | $124,122 |
| TymlosAbaloparatide | 25 | $73,900 |
| JardianceEmpagliflozin | 65 | $72,578 |
| FarxigaDapagliflozin Propanediol | 62 | $59,986 |
| XyostedTestosterone Enanthate | 52 | $58,935 |
| Tresiba Flextouch U-200Insulin Degludec | 34 | $38,205 |
| KerendiaFinerenone | 31 | $36,157 |
| JatenzoTestosterone Undecanoate | 28 | $33,608 |
| SynthroidLevothyroxine Sodium | 351 | $29,773 |
| Repatha SureclickEvolocumab | 25 | $29,740 |
| RybelsusSemaglutide | 21 | $27,601 |
| ProliaDenosumab | 15 | $26,203 |
| TrulicityDulaglutide | 19 | $24,713 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $1,121 | $351,047277 claims |
| Novo NordiskOzempic, Rybelsus | $1,772 | $173,841120 claims |
| PfizerGenotropin, Premarin | $188 | $127,26748 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Glyxambi | $390 | $100,30598 claims |
| Radius Health, Inc.Tymlos | $704 | $73,90025 claims |
| AstraZenecaFarxiga | $430 | $59,98662 claims |
| Antares Pharma, Inc.Xyosted | $4,143 | $58,93552 claims |
| BayerKerendia | $328 | $36,15731 claims |
| Clarus Therapeutics Inc.Jatenzo | $63 | $33,60828 claims |
| AbbVieSynthroid, Armour Thyroid | $452 | $31,772366 claims |
| AmgenProlia | $14,622 | $26,20315 claims |
| MerckJanuvia | $66 | $15,01218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 952 endocrinology, diabetes & metabolism providers in California.
Other endocrinology, diabetes & metabolism in Beverly Hills
- Anne PetersBeverly Hills$121K
- Reza NazemiBeverly Hills$97K
- Juan FriasSan Diego$1.4M
- Joselito CabaccanSan Jose$1.4M
- Daniel NadeauNewport Beach$1.2M
- Yehuda HandelsmanTarzana$1M
- Helen BaronRancho Mirage$958K
- Ken FujiokaSan Diego$747K
- Minou TranPico Rivera$663K
- James ChuMonterey$639K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.